|
US9833480B2
(en)
|
2010-04-14 |
2017-12-05 |
Prospect Chartercare, Llc |
Methods and compositions for treating HIV
|
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
US9402865B2
(en)
*
|
2011-01-18 |
2016-08-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating cancer
|
|
EP4541818A3
(en)
|
2012-05-25 |
2025-07-23 |
Cellectis |
Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
|
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
EP3763810A3
(en)
|
2012-10-10 |
2021-07-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
EP4282419A1
(en)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
JO3529B1
(ar)
*
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
SI3300745T1
(sl)
|
2013-02-15 |
2020-01-31 |
The Regents Of The University Of California |
Himerni antigenski receptor in postopki njihove uporabe
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
LT2958943T
(lt)
|
2013-02-20 |
2020-01-27 |
The Trustees Of The University Of Pennsylvania |
Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
EP2970426B1
(en)
|
2013-03-15 |
2019-08-28 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
RS63798B1
(sr)
|
2013-05-13 |
2022-12-30 |
Cellectis |
Cd19 specifični himerni antigenski receptor i njegove primene
|
|
EP3049515B1
(en)
*
|
2013-09-23 |
2019-03-13 |
Wilson Wolf Manufacturing Corporation |
Improved methods of genetically modifying animal cells
|
|
CN103589742A
(zh)
*
|
2013-11-07 |
2014-02-19 |
申峰 |
嵌合体抗原受体胞内段的基因及其编码蛋白
|
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
WO2015092024A2
(en)
*
|
2013-12-20 |
2015-06-25 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
WO2015112626A1
(en)
*
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
CA3190002A1
(en)
*
|
2014-02-14 |
2015-08-20 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
GB201405845D0
(en)
*
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
IL322264A
(en)
|
2014-04-07 |
2025-09-01 |
Novartis Ag |
Cancer treatment using chimeric antigen receptor (CAR) against CD19
|
|
AU2015243849B2
(en)
|
2014-04-10 |
2020-12-17 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Transgene genetic tags and methods of use
|
|
US20170158749A1
(en)
*
|
2014-04-23 |
2017-06-08 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (car) and methods for making and using the same
|
|
EP3738597A1
(en)
|
2014-04-25 |
2020-11-18 |
Bluebird Bio, Inc. |
Improved methods for manufacturing adoptive cell therapies
|
|
IL296691B2
(en)
|
2014-04-25 |
2023-11-01 |
2Seventy Bio Inc |
MND promoter chimeric antigen receptors
|
|
DK3166968T3
(da)
|
2014-05-02 |
2021-12-06 |
Univ Pennsylvania |
Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler
|
|
CN106793780B
(zh)
*
|
2014-06-06 |
2020-05-26 |
蓝鸟生物公司 |
改善的t细胞组合物
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
JP2017522884A
(ja)
*
|
2014-07-29 |
2017-08-17 |
ファイザー・インク |
がん免疫療法のためのＥＧＦＲｖＩＩＩ特異的キメラ抗原受容体
|
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
ES3034398T3
(en)
|
2014-08-28 |
2025-08-18 |
Bioatla Inc |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
ES2891332T3
(es)
|
2014-09-17 |
2022-01-27 |
Novartis Ag |
Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
|
|
AU2015330898B2
(en)
|
2014-10-08 |
2022-03-10 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
CN113736828A
(zh)
*
|
2014-11-05 |
2021-12-03 |
朱诺治疗学股份有限公司 |
用于转导及细胞处理的方法
|
|
EP3971210A1
(en)
|
2014-12-12 |
2022-03-23 |
2seventy bio, Inc. |
Composition for use in the treatment of b cell related conditions in a subject in need thereof comprisine an effector cell comrising a bcma chimeric antigen receptors
|
|
KR102923234B1
(ko)
*
|
2014-12-19 |
2026-02-04 |
다나-파버 캔서 인스티튜트 인크. |
키메라 항원 수용체 및 이의 사용 방법
|
|
CN107567461A
(zh)
|
2014-12-29 |
2018-01-09 |
诺华股份有限公司 |
制备嵌合抗原受体表达细胞的方法
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016120218A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016138034A1
(en)
|
2015-02-24 |
2016-09-01 |
The Regents Of The University Of California |
Binding-triggered transcriptional switches and methods of use thereof
|
|
AU2016243583B2
(en)
|
2015-03-27 |
2022-03-10 |
President And Fellows Of Harvard College |
Modified T cells and methods of making and using the same
|
|
MX2017012939A
(es)
|
2015-04-08 |
2018-05-22 |
Novartis Ag |
Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
|
|
AU2016249005B2
(en)
|
2015-04-17 |
2022-06-16 |
Novartis Ag |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP4316500A3
(en)
*
|
2015-05-13 |
2024-04-10 |
CSL Behring Gene Therapy, Inc. |
Bio-production of lentiviral vectors
|
|
BR112017024757A2
(pt)
|
2015-05-18 |
2018-11-13 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr utilizando proteínas de fusão
|
|
IL255887B
(en)
|
2015-05-28 |
2022-09-01 |
Kite Pharma Inc |
Methods for training patients for t-cell therapy
|
|
CN107921064A
(zh)
|
2015-05-28 |
2018-04-17 |
凯德药业股份有限公司 |
用于t细胞疗法的诊断方法
|
|
US10071118B2
(en)
*
|
2015-07-16 |
2018-09-11 |
Prospect Charactercare Rwmc, Llc |
Compositions and methods for treating peritoneal cancers
|
|
WO2017015427A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
JP7162530B2
(ja)
|
2015-08-07 |
2022-10-28 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
|
|
CN116334205A
(zh)
|
2015-09-03 |
2023-06-27 |
诺华股份有限公司 |
预测细胞因子释放综合征的生物标志物
|
|
SG11201802966TA
(en)
|
2015-10-20 |
2018-05-30 |
Kite Pharma Inc |
Methods of preparing t cells for t cell therapy
|
|
CN114231486A
(zh)
|
2015-10-30 |
2022-03-25 |
儿童国家医疗中心 |
从未致敏t细胞群体产生hpv抗原特异性t细胞
|
|
CN105331585A
(zh)
|
2015-11-13 |
2016-02-17 |
科济生物医药（上海）有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
|
US20210206826A1
(en)
*
|
2015-11-19 |
2021-07-08 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
|
US10724006B2
(en)
*
|
2015-11-19 |
2020-07-28 |
Novartis Ag |
Buffers for stabilization of lentiviral preparations
|
|
ES2862907T3
(es)
|
2015-11-27 |
2021-10-08 |
Cartherics Pty Ltd |
Células genéticamente modificadas y usos de las mismas
|
|
CN108699557B
(zh)
|
2015-12-04 |
2025-08-15 |
诺华股份有限公司 |
用于免疫肿瘤学的组合物和方法
|
|
WO2017099712A1
(en)
|
2015-12-07 |
2017-06-15 |
Bluebird Bio, Inc. |
Improved t cell compositions
|
|
GB201522097D0
(en)
|
2015-12-15 |
2016-01-27 |
Cellular Therapeutics Ltd |
Cells
|
|
PT3393504T
(pt)
|
2015-12-22 |
2025-12-30 |
Novartis Ag |
Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
|
|
SG11201804038VA
(en)
|
2016-01-08 |
2018-06-28 |
Univ California |
Conditionally active heterodimeric polypeptides and methods of use thereof
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
KR102608405B1
(ko)
|
2016-04-01 |
2023-12-01 |
카이트 파마 인코포레이티드 |
키메라 수용체 및 그의 사용 방법
|
|
US10689450B2
(en)
|
2016-04-01 |
2020-06-23 |
Kite Pharma, Inc |
BCMA binding molecules and methods of use thereof
|
|
US10603380B2
(en)
|
2016-04-01 |
2020-03-31 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
|
US12144850B2
(en)
|
2016-04-08 |
2024-11-19 |
Purdue Research Foundation |
Methods and compositions for car T cell therapy
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
CN121731464A
(zh)
|
2016-04-22 |
2026-03-27 |
克莱格医学有限公司 |
用于细胞免疫疗法的组合物和方法
|
|
CN118165113B
(zh)
*
|
2016-04-26 |
2025-10-28 |
恺兴生命科技(上海)有限公司 |
一种改善免疫应答细胞功能的方法
|
|
TWI851939B
(zh)
|
2016-05-13 |
2024-08-11 |
美商拜奧亞特拉公司 |
抗-ror2抗體、抗體片段、其免疫結合物及其用途
|
|
JP7373991B2
(ja)
|
2016-07-15 |
2023-11-06 |
ビラクタ セラピューティクス，インク． |
免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
WO2018026953A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018057585A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
|
WO2018067992A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
MX2019003899A
(es)
|
2016-10-07 |
2019-08-14 |
Tcr2 Therapeutics Inc |
Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
|
|
AU2017345764A1
(en)
|
2016-10-20 |
2019-05-02 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
WO2018075820A2
(en)
|
2016-10-20 |
2018-04-26 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
KR20240005168A
(ko)
|
2016-11-04 |
2024-01-11 |
2세븐티 바이오, 인코포레이티드 |
항-bcma car t 세포 조성물
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
US11408005B2
(en)
|
2016-12-12 |
2022-08-09 |
Seattle Children's Hospital |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN106749681A
(zh)
*
|
2017-02-10 |
2017-05-31 |
河南大学淮河医院 |
靶向人FRα的基因工程化NKT细胞及其制备方法和应用
|
|
US11046775B2
(en)
|
2017-02-14 |
2021-06-29 |
Kite Pharma, Inc. |
CD70 binding molecules and methods of use thereof
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
EP3596114A2
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
JP2020511144A
(ja)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
|
|
IL320149A
(en)
|
2017-03-16 |
2025-06-01 |
Alpine Immune Sciences Inc |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
KR20190130608A
(ko)
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
|
BR112019017629A2
(pt)
*
|
2017-03-27 |
2020-04-07 |
Hoffmann La Roche |
receptor de união ao antígeno, polinucleotídeo isolado, vetor, célula t transduzida, métodos para o tratamento de uma doença e para induzir a lise, utilização do receptor e receptor
|
|
ES2954311T3
(es)
|
2017-04-01 |
2023-11-21 |
Avm Biotechnology Llc |
Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular
|
|
SG11201908980PA
(en)
|
2017-04-03 |
2019-10-30 |
Kite Pharma Inc |
Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells
|
|
US11344578B2
(en)
|
2017-04-19 |
2022-05-31 |
Board Of Regents, The University Of Texas System |
Immune cells expressing engineered antigen receptors
|
|
PT3615146T
(pt)
|
2017-04-24 |
2023-11-27 |
Kite Pharma Inc |
Domínios de ligação ao antigénio humanizados contra cd19 e métodos de utilização
|
|
RU2019140867A
(ru)
|
2017-05-12 |
2021-06-15 |
Зе Джексон Лаборатори |
Nsg мыши, не имеющие mhc класса i и класса ii
|
|
AU2018281830B2
(en)
|
2017-06-09 |
2023-11-02 |
Agonox, Inc. |
Utilization of CD39 and CD103 for identification of human tumor reactive cells for treatment of cancer
|
|
CA3067914A1
(en)
|
2017-06-30 |
2019-01-03 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
AU2018313950A1
(en)
*
|
2017-08-09 |
2020-02-13 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
KR102521245B1
(ko)
*
|
2017-09-15 |
2023-04-17 |
카이트 파마 인코포레이티드 |
관리 연속성 및 신원 연속성 생물학적 샘플 추적으로 환자-특이적 면역요법 절차를 수행하기 위한 방법 및 시스템
|
|
CN111148533A
(zh)
|
2017-09-19 |
2020-05-12 |
麻省理工学院 |
用于嵌合抗原受体t细胞疗法的组合物及其用途
|
|
ES2980055T3
(es)
|
2017-09-22 |
2024-09-27 |
Kite Pharma Inc |
Polipéptidos quiméricos y usos de los mismos
|
|
WO2019074983A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
|
|
US11712026B2
(en)
|
2017-10-18 |
2023-08-01 |
The Jackson Laboratory |
Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
|
|
KR20200086278A
(ko)
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
JP7282760B2
(ja)
|
2017-10-18 |
2023-05-29 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法
|
|
KR20230011487A
(ko)
|
2017-10-18 |
2023-01-20 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 면역요법제를 투여하는 방법
|
|
CN111683962B
(zh)
|
2017-11-10 |
2025-05-16 |
美国政府(由卫生和人类服务部的部长所代表) |
靶向肿瘤抗原的嵌合抗原受体
|
|
WO2019099707A1
(en)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
|
CA3086832A1
(en)
|
2018-01-03 |
2019-07-11 |
Qu Biologics Inc. |
Innate targeting of adoptive cellular therapies
|
|
WO2019136179A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
KR20200110356A
(ko)
|
2018-01-15 |
2020-09-23 |
화이자 인코포레이티드 |
키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법
|
|
US11311576B2
(en)
|
2018-01-22 |
2022-04-26 |
Seattle Children's Hospital |
Methods of use for CAR T cells
|
|
JP2021513839A
(ja)
|
2018-02-16 |
2021-06-03 |
カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ |
改変された多能性幹細胞並びに製造方法及び使用方法
|
|
WO2019165121A1
(en)
|
2018-02-21 |
2019-08-29 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses therof
|
|
CA3091674A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
WO2019173324A1
(en)
|
2018-03-06 |
2019-09-12 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
CN115925952A
(zh)
|
2018-03-13 |
2023-04-07 |
东莞凡恩世生物医药有限公司 |
抗叶酸受体1抗体及其用途
|
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
|
CA3291067A1
(en)
|
2018-04-12 |
2025-11-29 |
Kite Pharma, Inc. |
Chimeric receptor t cell treatment using characteristics of the tumor microenvironment
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
SG11202011541SA
(en)
|
2018-06-01 |
2020-12-30 |
Kite Pharma Inc |
Chimeric antigen receptor t cell therapy
|
|
WO2019236593A1
(en)
*
|
2018-06-05 |
2019-12-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
AU2019284911B2
(en)
|
2018-06-13 |
2026-04-09 |
Novartis Ag |
BCMA chimeric antigen receptors and uses thereof
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
WO2020005837A1
(en)
*
|
2018-06-25 |
2020-01-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
|
|
JP7623939B2
(ja)
*
|
2018-07-09 |
2025-01-29 |
マルチチュード インコーポレーテッド |
葉酸受容体アルファに特異的な抗体
|
|
CA3107938C
(en)
|
2018-08-02 |
2024-04-30 |
Kite Pharma, Inc. |
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
|
|
CN110819703A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞安全性的方法
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
|
KR20210089146A
(ko)
|
2018-09-19 |
2021-07-15 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
변이체 cd80 단백질 및 관련 구축물의 방법 및 용도
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
|
CN112996809A
(zh)
*
|
2018-10-10 |
2021-06-18 |
酵活有限公司 |
结合4-1bb和肿瘤相关抗原的抗体构建体以及其用途
|
|
CN116286665A
(zh)
*
|
2018-11-16 |
2023-06-23 |
上海煦顼技术有限公司 |
嵌合抗原受体细胞分泌治疗剂
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
AU2019384145A1
(en)
*
|
2018-11-20 |
2021-06-10 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Modified cell expressing therapeutic agent and uses thereof
|
|
JP7278379B2
(ja)
|
2018-11-29 |
2023-05-19 |
ヴィネティ インク． |
集中型及び分散型の個別化医薬プラットフォーム
|
|
WO2020123716A1
(en)
|
2018-12-11 |
2020-06-18 |
Obsidian Therapeutics, Inc. |
Membrane bound il12 compositions and methods for tunable regulation
|
|
US11793834B2
(en)
|
2018-12-12 |
2023-10-24 |
Kite Pharma, Inc. |
Chimeric antigen and T cell receptors and methods of use
|
|
CN109796535B
(zh)
*
|
2019-01-30 |
2022-11-15 |
重庆福美干细胞生物科技发展有限公司 |
靶向叶酸受体α的嵌合抗原受体及其在制备预防或治疗恶性肿瘤药物中的用途
|
|
US11321652B1
(en)
|
2019-02-20 |
2022-05-03 |
Vineti Inc. |
Smart label devices, systems, and methods
|
|
KR20210149251A
(ko)
|
2019-03-08 |
2021-12-08 |
옵시디안 테라퓨틱스, 인크. |
조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
|
|
JP7654557B2
(ja)
*
|
2019-03-27 |
2025-04-01 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
Ｔｎ－ＭＵＣ１キメラ抗原受容体（ＣＡＲ）Ｔ細胞療法
|
|
AU2020267378B2
(en)
|
2019-05-03 |
2025-01-30 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|
|
CN114127287A
(zh)
*
|
2019-05-13 |
2022-03-01 |
宾夕法尼亚大学董事会 |
乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法
|
|
EP3973072A1
(en)
|
2019-05-23 |
2022-03-30 |
Vogelsang, Matjaz |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
|
WO2020252404A1
(en)
|
2019-06-12 |
2020-12-17 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
JP2022537670A
(ja)
|
2019-06-12 |
2022-08-29 |
オブシディアン セラピューティクス， インコーポレイテッド |
Ｃａ２の組成物および調整可能な制御方法
|
|
US12109235B2
(en)
|
2019-06-21 |
2024-10-08 |
Kite Pharma, Inc. |
TGF-beta receptors and methods of use
|
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
|
BR112022003852A2
(pt)
|
2019-09-03 |
2022-05-31 |
Allogene Therapeutics Inc |
Métodos de preparação de células t para terapia de células t
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
AU2020361683A1
(en)
*
|
2019-10-11 |
2022-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting CD13 and TIM-3 with CAR T cells to treat acute myeloid leukemia
|
|
CA3154281A1
(en)
*
|
2019-10-16 |
2021-04-22 |
Andrew Scharenberg |
Retroviral vector for universal receptor therapy
|
|
IL292665B2
(en)
|
2019-11-06 |
2026-02-01 |
Kite Pharma Inc |
Chimeric antigen receptor T cell therapy
|
|
KR20220104217A
(ko)
|
2019-11-26 |
2022-07-26 |
노파르티스 아게 |
Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
|
|
EP4065158A2
(en)
|
2019-11-26 |
2022-10-05 |
Novartis AG |
Chimeric antigen receptors binding bcma and cd19 and uses thereof
|
|
KR20220119439A
(ko)
|
2019-12-20 |
2022-08-29 |
인스틸 바이오 유케이 리미티드 |
종양 침윤 림프구를 분리하기 위한 장치 및 방법 및 그것의 용도
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
CA3173527A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021226551A1
(en)
|
2020-05-08 |
2021-11-11 |
Alpine Immune Sciences, Inc. |
April and baff inhibitory immunomodulatory proteins and methods of use thereof
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
WO2021260675A1
(en)
|
2020-06-24 |
2021-12-30 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
CA3189671A1
(en)
|
2020-07-17 |
2022-01-20 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
KR20230084470A
(ko)
|
2020-08-14 |
2023-06-13 |
카이트 파마 인코포레이티드 |
면역 세포 기능의 향상
|
|
CN116157868A
(zh)
*
|
2020-08-18 |
2023-05-23 |
德尔菲诊断公司 |
用于游离dna片段大小密度以评估癌症的方法和系统
|
|
EP4501951A3
(en)
|
2020-08-25 |
2025-04-30 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
KR20230074758A
(ko)
|
2020-09-24 |
2023-05-31 |
더 잭슨 래보라토리 |
면역 세포 요법을 평가하기 위한 인간화 마우스 모델
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
KR20230124656A
(ko)
|
2020-12-24 |
2023-08-25 |
카이트 파마 인코포레이티드 |
전립선암 키메라 항원 수용체
|
|
AU2022205653B2
(en)
|
2021-01-10 |
2025-05-22 |
Kite Pharma, Inc. |
T cell therapy
|
|
EP4294950A1
(en)
|
2021-02-20 |
2023-12-27 |
Kite Pharma, Inc. |
Gene markers for selecting immunotherapies
|
|
WO2022192439A1
(en)
|
2021-03-11 |
2022-09-15 |
Kite Pharma, Inc. |
Improving immune cell function
|
|
CN112794911B
(zh)
*
|
2021-04-14 |
2021-08-03 |
上海偌妥生物科技有限公司 |
人源化抗叶酸受体1抗体及其应用
|
|
CA3216056A1
(en)
|
2021-04-16 |
2022-10-20 |
Kite Pharma, Inc. |
Taci/bcma dual binding molecules
|
|
AR125461A1
(es)
|
2021-04-27 |
2023-07-19 |
Takeda Pharmaceuticals Co |
Células presentadoras de antígeno recombinante
|
|
IL308227A
(en)
|
2021-05-14 |
2024-01-01 |
Kite Pharma Inc |
Chimeric antigen receptor t cell therapy
|
|
US12331315B2
(en)
|
2021-05-24 |
2025-06-17 |
Kite Pharma, Inc. |
Chimeric antigen receptor
|
|
AU2022288058A1
(en)
|
2021-06-07 |
2023-11-16 |
Agonox, Inc. |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
CN117730100A
(zh)
|
2021-06-08 |
2024-03-19 |
凯德药业股份有限公司 |
Gpc3结合分子
|
|
US11945876B2
(en)
|
2021-06-16 |
2024-04-02 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
CN115572715A
(zh)
*
|
2021-06-21 |
2023-01-06 |
复星凯特生物科技有限公司 |
一种靶向folr1和her2双打靶点car t的制备及应用
|
|
EP4363558A1
(en)
*
|
2021-07-01 |
2024-05-08 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
|
EP4364151A1
(en)
|
2021-07-02 |
2024-05-08 |
Kite Pharma, Inc. |
A method for identifying variants in gene products from gene constructs used in cell therapy applications
|
|
WO2023288278A1
(en)
|
2021-07-16 |
2023-01-19 |
Instil Bio (Uk) Limited |
Chimeric molecules providing targeted costimulation for adoptive cell therapy
|
|
US11615874B1
(en)
|
2021-09-30 |
2023-03-28 |
Vineti Inc. |
Personalized medicine and therapies platform
|
|
US20260083848A1
(en)
|
2021-11-03 |
2026-03-26 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
IL313935A
(en)
|
2021-12-30 |
2024-08-01 |
Tr1X Inc |
CD4+ T cells expressing IL-10 chimeric antigen receptors and uses thereof
|
|
US20250134999A1
(en)
|
2022-01-14 |
2025-05-01 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
CA3247927A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
|
|
US20230296610A1
(en)
|
2022-02-15 |
2023-09-21 |
Kite Pharma, Inc. |
Predicting adverse events from immunotherapy
|
|
US20250243260A1
(en)
|
2022-03-07 |
2025-07-31 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies and related methods and uses
|
|
AU2023282907A1
(en)
|
2022-06-09 |
2024-11-14 |
Kite Pharma, Inc. |
Methods of preparing lymphocytes for cell therapy
|
|
CN119816590A
(zh)
|
2022-08-10 |
2025-04-11 |
武田药品工业株式会社 |
低免疫原性的经修饰细胞
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
TW202530421A
(zh)
|
2022-10-28 |
2025-08-01 |
美商凱特製藥公司 |
用於將免疫療法最佳化之因素
|
|
KR20250097844A
(ko)
|
2022-10-28 |
2025-06-30 |
카이트 파마 인코포레이티드 |
면역요법의 효능 향상 및 지속적인 반응
|
|
IL323071A
(en)
|
2023-03-17 |
2025-10-01 |
Kite Pharma Inc |
The influence of the tumor microenvironment on the effectiveness of immunotherapy
|
|
WO2024206549A2
(en)
*
|
2023-03-29 |
2024-10-03 |
Cellicure, Inc. |
Engineered immune cells and use thereof
|
|
WO2024224359A1
(en)
|
2023-04-27 |
2024-10-31 |
Takeda Pharmaceutical Company Limited |
Method for expanding cd56+/cd3- cells
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
US20250161361A1
(en)
|
2023-11-01 |
2025-05-22 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy efficacy
|
|
US20250290154A1
(en)
|
2024-03-04 |
2025-09-18 |
Kite Pharma, Inc. |
Predictive markers for immunotherapy
|
|
WO2026015450A1
(en)
|
2024-07-06 |
2026-01-15 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
WO2026069206A1
(en)
|
2024-09-25 |
2026-04-02 |
Takeda Pharmaceutical Company Limited |
Hypoimmunogenic modified gamma delta t cells
|
|
WO2026082736A1
(en)
|
2024-10-14 |
2026-04-23 |
Cimeio Therapeutics Ag |
Chimeric antigen receptor (car) that targets receptor-type tyrosine phosphatase c (cd45) and its use to related applications
|
|
WO2026096859A2
(en)
|
2024-11-04 |
2026-05-07 |
Kite Pharma, Inc. |
Biomarkers related to immunotherapy efficacy
|